Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Group, Lee Todd C, Barina Lauren A, Walls Genevieve, Goodman Anna L, Yahav Dafna, Cheng Matthew P, Bonten Marc, Bowen Asha C, Boyles Tom, Daneman Nick, Ekkelenkamp Miquel B, Ghanem-Zoubi Nesrin, Hensgens Marjolein P M, Jager Nynke G L, Kaasch Achim J, Kouijzer Ilse J E, Lewis Roger J, Lumley Thomas, Lye David C, McDonald Emily G, McKew Genevieve, McLean Alistair R D, McMullan Brendan J, McQuilten Zoe K, Morpeth Susan C, Paterson David L, Roberts Jason A, Robinson J Owen, Saito Hiroki, Scarborough Matthew, Ten Oever Jaap, Turner Rebecca M, Tverring Jonas, van Hal Sebastiaan J, Webb Steve A, Whiteway Lynda M, Arias Cesar A, Henderson Andrew, Heriot George S, Snelling Tom L, Afra Kevin, Ali Shabinah S, Amit Sharon, Anagnostou Nicholas A, Archuleta Sophia, Aston Stephen J, Athan Eugene, Baharav Nadav, Bai Anthony D, Barber Bridget E, Baskaran Abinayah, Berkeley Michelle M A, Best Emma J, Bhilave Nilesh R, Bloomfield Max G, Bond Katherine A, Bostock Jennifer, Botheras Carly L, Boyd Mark A, Bradshaw Sophia M E, Briggs Elizabeth J, Britton Philip N, Campbell Anita J, Carr Beau Z, Chancellor James A, Chen Kevin, Cheong Elaine Y, Chew Ka Lip, Chia Po Ying, Chomba Rispah, Chong Brian S W, Clews Chris J N, Cohen Jonathan M, Commons Robert J, Cutfield Tim, Daley Peter, Daniel Diane S, Davies Jane, De Partha, Denholm Justin T, Di Virgilio Mia, Dishon-Benattar Yael, Dotel Ravindra, Duan Erick H, Easom Nicholas, Eliakim-Raz Noa, England Michelle M, Fahmy Mark, Findlater Aidan R, Flanagan Katie L, Foo Ethan Z J, Foo Hong, Forster Daniel P, Fralick Michael, Frazer Jaimie L, Gador-Whyte Andrew P, Garnham Katherine, German Greg J, Ghosh Niladri, Gisolf Elisabeth H, Giulieri Stefano G, Goulding Susan R, Grant Jennifer M, Gregson Daniel, Grimwade Kate C, Grupper Mordechai, Guy Stephen D, Gwee Amanda, Hall Victoria G, Hardy Erica J, Harris David J, Hatcher James, Hobbs Mark R, Holmes Natasha E, Howden Benjamin P, Huggan Paul J, Jennings Zoe A, Johnstone Jennie, Juniper Thomas, Kalimuddin Shirin, Kamfose Musaiwale, Kandel Christopher, Kelly Matthew J, Kozak Robert A, Kümin Michelle, Lamontagne Francois, Lau Jillian S Y, Lee Ivor Russel, Lin Ray J, Lindsay Daisy, Llewelyn Martin J, Longtin Yves, Lother Sylvain A, Luey Christopher E, MacFadden Derek R, Mahony Andrew A, Malden Catherine, Malhamé Isabelle, Manning Laurens A, Marks Michael, Martin Leslie J, Matthews Gail V, McGann Patrick H, McMahon James H, Melon Alexandra, Menon Vidthiya, Mertz Dominik, Meyer Michael P, Molton James S, Mora Jocelyn M, Moran Ed, Mortimer Leanne M, Motaganahalli Satwik, Muller Matthew P, Munro Alasdair P S, Murray Fionnuala A, Murthy Srinivas, Nagendra Vanathi, Nel Henco, New David W J, Nguyen Vi, Norton Grace, Norton Katherine M, Nourse Clare B, Nye Clemency J S, O'Callaghan Kevin, O'Sullivan Matthew V N, Ong Sean W X, Otu Akaninyene A, Owen Melissa, Papenburg Jesse, Parkes Leighanne O, Paul Mical, Perez-Patrigeon Santiago, Petersiel Neta, Petrella Lina, Pett Sarah L, Pham David, Piazzese Chiara J, Poulin Sebastien, Rehak Renata, Rennert-May Elissa, Richards Alexander J, Rogers Benjamin A, Sahng Euna, Salada Brenda, Scheuerman Oded, Schneider Kellie, Schulz Thomas R, Schwartz Kevin L, Simos Peter A, Singh Harsimran, Sinkeler Fleur S, Smith Simon, Smith Benjamin J, Smith Stephanie W, Somayaji Ranjani, Sommerville Christine, Song Rima X J, Sowden David C, Stark Michael J, Stone Neil R H, Strunk Tobias, Sud Archana, Swe Khine P, Symons Caitlin R, Tan Yen Ee, Ten Doesschate Thijs, Thien Siew Yee, Thomas Ashmitha, Trad Mohamad-Ali, Tramontana Adrian R, Tsang Jennifer L Y, Ulett Kimberly, Underwood Jonathan, van Welzen Berend J, Vazquez-Grande Gloria, Velasquez Reyes Diana C, Verberk Janneke D M, Voss Lesley M, Ward Denise, Webb Rachel H, Whitmore Timothy J, Wieder-Finesod Anat, Wilson Heather L, Wilson Evan W, Wong Hei Man, Wong She Kate, Wuerz Terence, Yamamura Deborah L, Yeoh Alastair, Yow Boris Long Hei, Dymock Michael, Mahar Robert K, McGlothlin Anna, Marsh Julie A, Davis Joshua S, Tong Steven Y C
Аннотация
METHODS: In an ongoing international Bayesian adaptive platform trial, we conducted an open-label, randomized comparison of cefazolin with an antistaphylococcal penicillin (flucloxacillin or cloxacillin) in adult patients with penicillin-resistant, methicillin-susceptible S. aureus bacteremia. The primary outcome, which was evaluated with a hierarchical Bayesian logistic-regression model, was death from any cause within 90 days after enrollment in the platform. We assessed the posterior probability of the noninferiority of cefazolin to flucloxacillin or cloxacillin (with the criterion for noninferiority prespecified as an adjusted odds ratio of <1.2, which approximates an absolute difference in mortality of <2.5 percentage points if mortality in the antistaphylococcal-penicillin group is 15%), as well as the posterior probability of superiority (with the criterion of an adjusted odds ratio of <1.0). Secondary safety outcomes included the development of acute kidney injury within 14 days.
RESULTS: This domain of the ongoing trial was conducted between February 17, 2022, and August 7, 2024, by which time the criterion for noninferiority had been met. Mortality at 90 days among adults who could be evaluated was 15.0% (97 deaths among 645 patients) in the cefazolin group and 17.0% (109 deaths among 642 patients) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.81; 95% credible interval, 0.59 to 1.12; probability of noninferiority, 99.2%; probability of superiority, 89.8%). Acute kidney injury occurred in 92 of 660 patients (13.9%) in the cefazolin group, as compared with 127 of 648 (19.6%) in the antistaphylococcal-penicillin group (adjusted odds ratio, 0.67; 95% credible interval, 0.50 to 0.89; probability of superiority, 99.7%).
CONCLUSIONS: In patients with methicillin-susceptible S. aureus bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin with respect to 90-day mortality and was associated with a lower incidence of acute kidney injury. (Funded by the National Health and Medical Research Council and others; SNAP ClinicalTrials.gov number, NCT05137119.).